DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Fasinumab is an investigational drug.
There have been 10 clinical trials for Fasinumab. The most recent clinical trial was a Phase 1 trial, which was initiated on July 1st 2017.
The most common disease conditions in clinical trials are Osteoarthritis, Osteoarthritis, Hip, and Osteoarthritis, Knee. The leading clinical trial sponsors are Regeneron Pharmaceuticals, Teva Pharmaceutical Industries, Ltd., and Mitsubishi Tanabe Pharma Corporation.
There are two US patents protecting this investigational drug.
Recent Clinical Trials for Fasinumab
|Study to Evaluate Arthroplasty Specimens for Osteoarthritis of the Knee and Hip||Teva Pharmaceutical Industries, Ltd.||Phase 2|
|Study to Evaluate Arthroplasty Specimens for Osteoarthritis of the Knee and Hip||Regeneron Pharmaceuticals||Phase 2|
|To Assess the Patients' Ability to Self-Administer Fasinumab in an Unsupervised Setting||Regeneron Pharmaceuticals||Phase 3|
Top disease conditions for Fasinumab
Top clinical trial sponsors for Fasinumab
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Fasinumab||Start Trial||Binding-triggered transcriptional switches and methods of use thereof||The Regents of the University of California (Oakland, CA)||Start Trial|
|Fasinumab||Start Trial||Cell culture medium||LA JOLLA BIOLOGICS, INC. (San Diego, CA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|